• Police seek suspects in deadly birthday party shooting
  • Lawmakers launch inquires into U.S. boat strike
  • Nov. 29, 2025, 10:07 PM EST / Updated Nov. 30, 2025,…
  • Mark Kelly says troops ‘can tell’ what orders…

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

Savewith a NBCUniversal ProfileCreate your free profile or log in to save this articleOct. 6, 2025, 6:07 PM EDTBy Erika EdwardsThe booming IV hydration spa industry operates with virtually no oversight or data backing up its claims, according to the first comprehensive national analysis of hydration clinics. At clinics nationwide, people pay hundreds of dollars to have vitamins and minerals dripped directly into their veins as a detox, to ease headaches or boost immunity, “almost completely without evidence,” said Dr. Peter Lurie, president of the Center for Science in the Public Interest and co-author of the study, published Monday in JAMA Internal Medicine. “As a result, there’s a real danger to consumers.”Hydration clinics, combined with the growing number of med spas offering intravenous vitamin drips, skin care and cosmetic procedures, have ballooned into a $15 billion wellness industry in recent years, according to the American Med Spa Association. The group represents med spas, which often offer IV treatments, nationwide. Alex Thiersch, chief executive officer of the American Med Spa Association, said some IV hydration clinic providers don’t realize that they’re actually practicing medicine and may lack proper training.“We have had folks who are surprised by that,” Thiersch said. “They thought, ‘I’m just doing an IV. It’s different. It’s vitamins.’”“If you’re putting a needle in someone’s vein,” he said, “that’s 100% medical practice.”There are no federal health regulations or national standards for procedures for med spas. Instead, the facilities fall under the authority of each state.As of June 2024, no state or jurisdiction had enacted legislation specifically to regulate IV hydration spas, according to the new study.Thirty-two states did have some kind of policy addressing IV hydration spas, including rules either for prescribing or compounding drugs or how clinics should dispense medications.Four states — Alabama, North Carolina, South Carolina and Vermont — had the most comprehensive oversight. “This is a medical system that exists largely outside of conventional medicine,” Lurie said. “We’re worried that people will spend their money on these without reason to expect benefits. We’re also worried that there will be adverse effects related to this.”The potential for injury is real: Products or equipment could be contaminated, or a provider might not have appropriate training to give an IV safely.There’s no official count of the number of people injured at med spas. Infections and allergic reactions aren’t often reported to health departments. The new research cited NBC News’ previous reporting on med spas as evidence of “rising concerns of their safety, with reports of infections and contaminated products.” Of 255 clinic websites analyzed, more than half offered IV hydration therapy touting therapies like magnesium for headaches and muscle cramps, glutathione as a potential immune system booster, or other substances advertised to increase energy.Just two of those sites listed tangible sources for those health claims. None mentioned potential risks, like infection or allergic reactions. One aspect of the research involved a secret shopper investigation, in which researchers placed calls to 87 randomly chosen spas.Only about 1 in 4 required a medical consultation beforehand. More than 85% recommended specific IV cocktails when callers mentioned symptoms like a headache or cold, often without verifying a patient’s medical history.Fewer than 1 in 4 warned about potential side effects, like bruising or infections. The Food and Drug Administration previously warned consumers about the potential for severe infections and skin deformities from unauthorized shots touted to dissolve fat at med spas.Erika EdwardsErika Edwards is a health and medical news writer and reporter for NBC News and “TODAY.”

admin - Latest News - October 6, 2025
admin
25 views 15 secs 0 Comments




The booming IV hydration spa industry operates with virtually no oversight or data backing up its claims, according to the first comprehensive analysis of the spa clinics.



Source link

TAGS:
PREVIOUS
The AI boom's reliance on circular deals is raising fears of a bubble
NEXT
Oct. 6, 2025, 7:40 PM EDTBy Zoë RichardsPresident Donald Trump said Monday that he would consider invoking the Insurrection Act “if it was necessary,” particularly if the courts or state and local officials delay his plans to deploy the National Guard.”I’d do it if it was necessary. So far it hasn’t been necessary. But we have an Insurrection Act for a reason,” Trump told reporters in the Oval Office when he was asked under what conditions he would consider the rarely used 19th century law.”If I had to enact it, I’d do that. If people were being killed and courts were holding us up or governors or mayors were holding us up, sure, I’d do that. I mean, I want to make sure that people aren’t killed. We have to make sure that our cities are safe,” he added.The Insurrection Act of 1807 allows the president to mobilize the U.S. military to conduct civilian law enforcement activities under certain circumstances. It was last used during the 1992 Los Angeles riots.Trump was speaking about his efforts to federalize troops and crack down on crime in Democratic-run cities.A federal judge in Oregon on Sunday blocked the Trump administration from deploying federalized National Guard members from California or other states to Portland’s streets.U.S. District Judge Karin Immergut, a Trump appointee, had also blocked the administration from deploying Oregon National Guard troops in Portland.”Portland’s been on fire for years, and not so much saving it,” Trump told reporters Monday. “We have to save something else, because I think that’s all insurrection. I really think that’s really criminal insurrection.”Oregon AG: Trump shouldn’t deploy troops to cities unless under ‘extreme circumstances’02:44Trump and his allies similarly referred to protesters opposing Immigration and Customs Enforcement raids in Los Angeles as “insurrectionists,” and Trump offered a similar answer in June when he was asked about any plans to invoke the Insurrection Act. “Depends on whether or not there’s an insurrection,” he said at the time, without ruling out the possibility of using it in the future.A key Trump ally argued earlier Monday that such action is needed now.In a text message to NBC News before Trump’s Oval Office remarks, former White House strategist Steve Bannon said Trump “needs to invoke the Insurrection Act of 1807 immediately and deploy active duty U.S. Army personnel and assets to Portland and Chicago — he needs to put Pritzker and Newsom in their place.”California Gov. Gavin Newsom and Illinois Gov. JB Pritzker, both Democrats, have opposed Trump’s National Guard efforts in their states.At a news conference earlier Monday, Pritzker suggested that Trump is trying to sow unrest so he can invoke the Insurrection Act.”The Trump administration is following a playbook cause chaos, create fear and confusion, make it seem like peaceful protesters are a mob by firing gas pellets and tear gas canisters at them,” Pritzker said. “Why? To create the pretext for invoking the Insurrection Act so that he can send military troops to our city.”Illinois sued Monday to block the Trump administration from deploying federalized National Guard troops to Chicago. A judge declined to immediately block the administration’s move and instead scheduled a hearing for Thursday.White House spokeswoman Abigail Jackson said in a statement that Pritzker had failed to address violence in his state.“Amidst ongoing violent riots and lawlessness, that local leaders like Pritzker have refused to step in to quell, President Trump has exercised his lawful authority to protect federal officers and assets,” Jackson said. “President Trump will not turn a blind eye to the lawlessness plaguing American cities.”During his first term, despite nudging from allies, Trump ultimately did not invoke the Insurrection Act, which the White House said was a possibility in response to demonstrations stemming from the death of George Floyd in Minneapolis in May 2020.Zoë RichardsZoë Richards is a politics reporter for NBC News.Katherine Doyle and Dareh Gregorian contributed.
Related Post
November 27, 2025
Nov. 27, 2025, 6:00 AM ESTBy Akshay Syal, M.D.For decades, doctors have been puzzled by why women develop Alzheimer’s disease at nearly twice the rate of men. There are an estimated 7 million people in the U.S. living with Alzheimer’s, with that number expected to reach nearly 13 million by 2050. A majority of cases, or about 2 out of every 3, are in women. An emerging body of research is suggesting that estrogen, the predominant female sex hormone, may play a critical role, specifically in the perimenopausal transition to menopause, when the body’s hormone levels naturally begin to decline. Estrogen is thought to perform a variety of functions in the body, such as improving cardiovascular health and maintaining bone density. Estrogen is very important to the brain and is considered neuroprotective, helping shield brain cells from inflammation, stress and other forms of cellular damage. Alzheimer’s researchers are focused on the early period of perimenopause, which typically occurs in a woman’s early- to mid-40s, as a target for hormone replacement therapy to maintain estrogen levels and possibly protect some women against developing dementia decades later. “This interest comes primarily from decades of pre-clinical research, animal models, and basic science research showing that menopause is a tipping point for Alzheimer’s pathology,” said Lisa Mosconi, director of the Alzheimer’s Prevention Program at Weill Cornell Medicine. Mosconi is leading a new $50 million global women’s health research initiative called CARE, or Cutting women’s Alzheimer’s risk through endocrinology. Looking at biomarkers from nearly 100 million women, it’s expected to be the largest analysis of why women are at greater risk of Alzheimer’s disease. The link between estrogen and dementia has gained renewed focus after the Food and Drug Administration recently lifted the decades-old black-box warning on hormone replacement therapy, a move that may lead to many more women in their 40s and 50s being prescribed treatment. Doctors say loosened restrictions could reduce stigma around hormone therapy. The FDA’s move could also pave the way for broader research into whether hormone replacement therapy might offer additional benefits, including protection against dementia. Declining reproductive hormonesMenopause occurs when the ovaries gradually produce less estrogen and progesterone, hormones that help regulate the menstrual cycle. Estrogen and progesterone are sex hormones that are present in females and to a lesser extent in males that play an important role in sexual and reproductive development. Most women reach menopause between the ages of 45 and 55, said Dr. Monica Christmas, a gynecologist and director of the menopause program at UChicago Medicine. The transition can begin years earlier during perimenopause, which usually starts when women are in their mid-40s. That’s when symptoms such as hot flashes, night sweats, mood changes and sleep disturbances often appear. It’s thought that menopause symptoms are caused by decreased levels of estrogen and progesterone in the body. For example, when estrogen levels drop, the body’s internal thermostat, controlled by the hypothalamus in the brain, begins to not work properly. The brain might interpret the body as too hot and tell it to start sweating to cool off, leading to symptoms of hot flashes. Hormone therapy can replenish those levels and help the body regulate its temperature. What role does estrogen play?Receptors for this sex hormone are found throughout our brains, said Rachel Buckley, an associate professor of neurology at Massachusetts General Hospital whose research focuses on sex differences in Alzheimer’s disease. “Estrogen is actually a really powerful hormone,” she said. “It’s found in the hippocampus which is an area [in the brain] that we know is very closely associated with memory and learning.” Estrogen also helps to build and maintain healthy blood flow in the brain, she added, and can even help the brain use energy more efficiently. During menopause, however, the levels of estrogen begin to decline, potentially leaving the brain more vulnerable to damage. “Once the brain loses the protective effects of estrogen and other sex hormones, it’s a turning point for Alzheimer’s pathology accumulation in the brain,” said Mosconi. Can hormone replacement therapy fight dementia?Hormone replacement therapy is available in many forms, including a wearable patch, cream and pills, and can include either estrogen, progesterone, or both. If estrogen helps protect our brain, it would make sense that replacing levels through hormone therapy might confer some sort of benefit. It turns out, however, the answer is much more complicated than that, experts say, as the research behind hormone replacement therapy is mixed and ongoing.However, data suggests that the perimenopause transition might represent a critical window of opportunity where treatment could help some patients ward off dementia, said Dr. Kellyann Niotis, a preventive neurologist in Florida and faculty member at Weill Cornell Medicine. “One leading belief is that during this perimenopausal window hormones are fluctuating rapidly and you can have steep declines in [estrogen] which can be harmful for the brain,” said Niotis.“The idea is that using hormones at a steady state or consistent level kind of helps even out those fluctuations.” A large analysis from Mosconi and her team in 2023 published in Frontiers in Aging Neuroscience found that there may be a sweet spot for initiation of HRT for helping women fight cognitive decline.Her team analyzed over 50 studies and found that people using estrogen therapy in midlife, or within 10 years of their final menstrual period, had a significantly lower risk of dementia. Conversely, when combination hormone therapy was initiated after 65, there was an increased risk of dementia. Another large-scale analysis of 50 studies presented this fall at the American Neurological Association annual meeting found that the risk of Alzheimer’s was up to 32% lower among women who started HRT within five years of menopause than in those who received a placebo or no treatment. The paper is not yet peer-reviewed or published in a journal. The research, which was done by scientists based in India, also found that among women who waited until they were 65 or older to start therapy, there was a 38% increase in Alzheimer’s risk. However, many of the studies performed to date have been observational, said Christmas, and do not directly prove a cause and effect relationship. More rigorous research including large scale trials are needed, she added. Hormone therapy that is prescribed may also not behave exactly like estrogen that is produced naturally by the body, she added, and also requires further study.Why timing of hormone therapy mattersThe theory of a critical window to initiate hormone replacement therapy may be related to estrogen receptors in the brain, said Mosconi. During the transition to menopause, there becomes a progressively higher density of estrogen receptors on brain cells, her research has found. This is because, as estrogen levels naturally decline, the brain increases the amount of available receptors as a compensatory mechanism to try and grab every little bit of estrogen that’s still available to be used up, she said. But at some point, when estrogen is permanently low, the brain ultimately stops trying and gives up, and the estrogen receptors disappear, she added. “That is the end of the window of opportunity because once the estrogen receptors are gone, there’s no point putting estrogen back in the system because it has nothing to bind to,” said Mosconi.Some outstanding questions remain, including how long women would need to stay on hormone replacement therapy or whether estrogen would be more protective for women with a genetic predisposition to Alzheimer’s. It’s also unclear if the brain responds differently to estrogen the body makes compared to hormone replacement. Men, on the other hand, have biologically different brains than women, said Buckley, as they have significantly less estrogen receptors and thus have a lower requirement of the hormone. It’s also unclear if testosterone replacement therapy for men confer any potential benefit for Alzheimer’s prevention, said Niotis. While some studies have suggested an association between men with lower testosterone and dementia, much more research is needed before any definitive conclusions can be made. Experts say it’s still too early to recommend hormone replacement therapy to prevent Alzheimer’s disease.“We do not use hormone therapy for Alzheimer’s prevention right now,” said Mosconi. “Clinical guidelines currently do not endorse using hormone therapy only for Alzheimer’s prevention.” Instead, HRT should be prescribed primarily to treat moderate to severe menopausal symptoms that can affect quality of life, such as hot flashes, night sweats, sleep disturbances or mood changes. Niotis said relieving these symptoms may help improve cognition, as people who sleep better have improved mood and tend to think more clearly. Still, she is optimistic that future research may bring more definitive answers. “The hope is that with the removal of this black-box warning that we’ll have more women that are starting therapies and are less afraid of using them, and more doctors that are less afraid of prescribing them,” said Niotis. Akshay Syal, M.D.Dr. Akshay Syal is a board-certified internal medicine physician at UCLA Health and instructor of medicine at the David Geffen School of Medicine at UCLA. He also is a member of the NBC News Health Unit, reporting for both NBC News Digital and on air for NBC News NOW and MSNBC.  
October 8, 2025
Oct. 8, 2025, 5:00 AM EDTBy Angela Yang and Jared PerloLynn White was out of options. Behind on payments for her mobile home in Long Beach, California, and facing an eviction notice, she had no money for a lawyer. So she accepted a court-appointed attorney and lost.But White wanted to appeal. So, she decided to consult ChatGPT. Having previously used AI to generate videos for her small music production business, she thought it might be able to help in the legal arena, too.“It was like having God up there responding to my questions,” White said after using the chatbot and an AI-powered search engine called Perplexity to help represent herself in court.
October 28, 2025
Trump says he had an MRI during October checkup
November 26, 2025
Nov. 25, 2025, 6:33 PM ESTBy Berkeley Lovelace Jr.The Centers for Medicare and Medicaid Services on Tuesday announced lower prices on 15 costly prescription drugs under Medicare, including Ozempic and Wegovy. The price cuts come through the Medicare drug price negotiation program created under the Inflation Reduction Act, which President Joe Biden signed into law in 2022. It’s different from President Donald Trump’s “most favored nation” drug pricing approach, which relies on executive orders and voluntary deals with drugmakers — not legislation. Trump recently announced such a deal with Novo Nordisk, the maker of Ozempic and Wegovy, to lower the price of the drugs in exchange for tariff relief.The Trump administration has been largely quiet about the Medicare price negotiation program.This is the second round of negotiations. Last year, the Biden administration reached deals on 10 prescription drugs, including several for heart disease and diabetes. Those price cuts are set to take effect in 2026. This latest round of price negotiations will go into effect in 2027.“President Trump directed us to stop at nothing to lower health care costs for the American people,” Health and Human Services Secretary Robert F. Kennedy Jr. said in a news release. “As we work to Make America Healthy Again, we will use every tool at our disposal to deliver affordable health care to seniors.” Drugmakers can choose not to strike deals under the negotiation program, but doing so would most likely mean withdrawing their drugs from Medicare — cutting them off from one of the nation’s largest markets. Drugmakers have challenged the program in court but so far have been unsuccessful. The negotiated prices are what Medicare will pay drugmakers for the medicines, not what patients will pay out of pocket. Those discounts will save taxpayers $12 billion, according to CMS. It’s expected to save Medicare enrollees $685 million in out-of-pocket costs in 2027. Here are the negotiated prices for the drugs, based on a 30-day supply, compared to the 2024 list price:Ozempic, Rybelsus and Wegovy, for Type 2 diabetes and weight loss: $274 negotiated price, down from the $959 list price. (Negotiated prices for higher doses of Wegovy are $385.)Trelegy Ellipta, an asthma treatment: $175, down from $654.Xtandi, for prostate cancer: $7,004, down from $13,480.Pomalyst, a chemotherapy drug: $8,650, down from $21,744.Ofev, for idiopathic pulmonary fibrosis: $6,350, down from $12,622.Ibrance, a breast cancer drug: $7,871, down from $15,741.Linzess, a chronic constipation drug: $136, down from $539.Calquence, a cancer drug: $8,600, down from $14,228.Austedo and Austedo XR, for Huntington’s disease: $4,093, down from $6,623.Breo Ellipta, a COPD drug: $67, down from $397.Xifaxan, for diarrhea and irritable bowel syndrome: $1,000, down from $2,696.Vraylar, an antipsychotic drug: $770, down from $1,376.Tradjenta, a diabetes drug: $78, down from $488. Janumet and Janumet XR, diabetes drugs: $80, down from $526.Otezla, a psoriatic arthritis drug: $1,650, down from $4,722.The 15 drugs accounted for $42.5 billion, or 15%, of total Medicare Part D spending in 2024. Medicare Part D covers medications that people take at home, as opposed to those administered in a facility, such as IV chemotherapy. “The price negotiations look very reasonable to me,” said Stacie Dusetzina, a health policy professor at Vanderbilt University in Nashville, Tennessee. “It should hopefully provide some relief for taxpayers and beneficiaries in the long run.” Dusetzina said the $274 negotiated price for Ozempic and Wegovy is higher than the $250 price in Trump’s deal. “They should’ve gotten that deal for the taxpayers and the Medicare beneficiaries,” she said.The price cuts come as many Americans say the cost of prescription drugs is unaffordable.About 1 in 5 adults say they’ve skipped filling a prescription because it was too expensive, according to a survey published in July by health policy research group KFF. About 1 in 7 say they have cut pills in half or skipped doses of medicine in the last year because of the cost. Berkeley Lovelace Jr.Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved